Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-06-27 | Reverse | 1:28 |
| 2021-07-27 | Reverse | 1:4 |
| 2020-10-30 | Reverse | 1:20 |
Indaptus Therapeutics, Inc., a New York-based pre-clinical biotech, develops anti-cancer and anti-viral immunotherapies, with its lead candidate Decoy20 in Phase I trials for various cancers and viral infections.

Decoy20, Indaptus Therapeutics' lead immunotherapy in Phase 1 trials, uses proprietary bacteria-based technology to activate immune responses against advanced solid tumors and infections.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
GTBP | $0.30 | COMPARE |
REVB | $1.05 | COMPARE |
PTIX | $0.98 | COMPARE |
ATXI | $0.45 | COMPARE |
NKGN | $0.00 | COMPARE |
SLXN | $0.36 | COMPARE |
PBM | $4.21 | COMPARE |
LIPO | $0.00 | COMPARE |